$ANIK

Anika Therapeutics (ANIK) shares rose 43.4% over the past 3 months, driven by optimism around its commercial products, pipeline progress, and improving financial outlook. The company reported strong Q2 2026 results with total revenues up 16% YoY, and raised its 2026 guidance. ANIK's pipeline includes Cingal and Hyalofast, with regulatory progress ongoing. The company adopted a conservative 2027 outlook, excluding unapproved products from forecasts.

Fischetti Gary P purchased 2,000 shares of Anika Therapeutics, Inc. (ANIK) at an average of $20.53 ($20.32–$20.74) across 2 trades over 2026-08-03 to 2026-08-04.

Biotech shares hit 52-week highs on Aug. 3-4, 2026, led by catalysts including upcoming quarterly reports and clinical-trial updates. AngioDynamics (ANGO) reached $15.41, citing FDA clearance for its RELIEF study and FY2026 net sales of $320.2 million. Anika (ANIK) hit $21.11 after Q2 revenue rose to $32.6 million. Pulse (PLSE) rose to $38.29 ahead of Aug. 6 results; Eloxx (ELOX) and Yarrow (YARW) also reached highs.

Strategic Execution and Operational Drivers Achieved record commercial channel revenue growth of 17%, fueled by focused portfolio alignment and strong international demand for CINGAL and MONOVISC. Expanded gross margins to 65% by implementing a lean transformation that doubled throughput on key manufacturing lines and improved production yields.

Anika Therapeutics, Inc. (ANIK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Anika Reports Second Quarter 2026 Financial Results Commercial Channel Revenue Increased 17% to a Record $13.9 Million Delivered $3.3 Million of Net Income, 65% Gross Margin, and $7.1 Million of Adjusted EBITDA, Highest Since 2020 Raising Full-Year 2026 Financial Gui

Anika Therapeutics, Inc. (ANIK) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 exh_101.htm EXHIBIT 10.1 Exhibit 10.1 Execution Version FIFTH AMENDMENT TO CREDIT AGREEMENT This FIFTH AMENDMENT TO CREDIT AGREEMENT , dated as of July 10, 2026 (this “ Fifth Amendment ”), is entered into among ANIKA THERAPEUTICS, INC. , a Delaware corporation (the “ Bo

Anika Therapeutics, Inc. (ANIK) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 exh_101.htm EXHIBIT 10.1 Exhibit 10.1 ANIKA THERAPEUTICS, INC. 2017 OMNIBUS INCENTIVE PLAN Anika Therapeutics, Inc. sets forth herein the terms of its 2017 Omnibus Incentive Plan. 1. PURPOSE The Plan is intended to enhance the ability of the Company and its Affiliates t

Anika Therapeutics' CEO, Stephen Griffin, acquired 12,200 shares of the company's common stock for $149,880 after a recent stock drop. This purchase increased his direct holdings to 36,163 shares and occurred despite the company reporting strong Q1 2026 financial results that exceeded expectations. The context suggests a CEO's confidence in the company following a market dip.

Anika Therapeutics' President and CEO, Stephen D. Griffin, purchased 12,200 shares of the company's common stock on April 30, 2026, at a weighted average price of $12.2853 per share, totaling approximately $150,000. Following this open-market transaction, Griffin directly holds 36,163 shares of ANIK. This insider buying signals positive sentiment from the company's leadership regarding its prospects.

Anika Therapeutics (ANIK) reported Q4 2025 revenue of US$30.6 million and basic EPS of US$0.13, showing a shift towards profitability from previous losses. Despite this positive quarterly performance, the company's trailing twelve-month revenue was US$112.8 million with a net loss of US$10.0 million and basic EPS of -US$0.70. Analysts predict Anika will remain unprofitable for the next three years, though its current P/S ratio and valuation suggest potential upside if it achieves promised profit margins.